Hikal starts construction of multiproduct API plant

Published: 28-Oct-2011
Manufacturing Ingredients

Will be operational by June 2012

Hikal, an Indian supplier of active ingredients and intermediates to the pharmaceutical industry, has started construction of a new multipurpose, multiproduct API plant, which will be operational by June 2012.

The flexible plant will be able to manufacture four APIs simultaneously under GMP and consists of two parallel streams running simultaneously with quick changeover capability.

The plant will also be able to accommodate 32 reactors with capacities ranging from 6m3 to 10m3, resulting in a total reactor volume of approximately 300m3.

A wide range of reactions will be carried out in the new plant, including nitration, liquid phase Oppenauer oxidation, Swern oxidation, Suzuki reaction, chiral synthesis, Mannich reaction, Friedel Craft reactions and more.

The firm says the reactors will be a combination of stainless steel and glass lined. Equipment for isolation and drying such as agitated nutsch filters, centrifuges and various types of dryers will also be installed.

Hikal has five manufacturing facilities in India at Maharashtra (Taloja and Mahad), Gujarat (Panoli) and Bangalore (Jigani), including an r&D centre and a dedicated contract research facility, Acoris Research, in Pune.

See more

You may also like

Ingredients

Hikal completes third US FDA audit in Bangalore

Read more
Indian ingredients manufacturer will ramp up new products under validation

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    Moving with speed and scale: innovative, material-sparing approaches to accelerate clinical development As early-stage drug development is often hindered by limited API supply, rising costs and tight timelines, material-sparing technologies are helping companies to progress faster with less
  2. Why weight sorting should move earlier in OSD development Phillip Ruda explains how earlier weight intelligence can improve process understanding, reduce risk and accelerate learning cycles
  3. Lyocontract invests €50m in new freeze-drying facility with Syntegon vial line German CDMO Lyocontract has begun construction of a €50m expansion in Ilsenburg, partnering with Syntegon to install a complete vial filling and lyophilisation line for sterile freeze-dried pharmaceuticals
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    The evolution of the CDMO model in Central Europe: strategic partnerships as a catalyst for change As the Central European outsourcing market matures, companies such as Mabion are redefining the CDMO paradigm with integrated biologics expertise and long-term codevelopment partnerships that elevate the region from cost-efficient manufacturer to strategic biopharma collaborator
  5. Compliance podcast: How EU law, AI and decentralised manufacturing are redefining the QP role On the NSF Life Sciences Compliance Podcast, Dr Peter Gough speaks on where pharmaceutical quality is headed next

Upcoming event

DCAT Week

23–26 March 2026 | Conference | New York, US See all

You may also like

Ingredients

Hikal completes third US FDA audit in Bangalore

Indian ingredients manufacturer will ramp up new products under validation
Media

Acoris and c-LEcta to develop synthetic routes for chiral compounds

<p>Acoris Research, a subsidiary of Hikal, and c-LEcta, a German industrial biotech company, are to collaborate on developing synthetic routes for chiral compounds. The partnership combines the expertise of Acoris in process development and small-scale manufacturing with the biocatalysis technologies of c-LEcta.</p>
Ingredients

Hikal signs API contract manufacturing agreement with Pfizer

<p>Indian outsourcing company Hikal has completed a contract manufacturing agreement for supply of active pharmaceutical ingredients (APIs) with Pfizer. Terms of the agreement were not disclosed.</p>
Manufacturing

Abzena named a leader in Frost & Sullivan ADC CDMO radar report

Recognition highlights integrated capabilities, proprietary technology and expertise in antibody-drug conjugates
Manufacturing

LabVantage Solutions introduces LabVantage CORTEX, advancing its LIMS platform for AI-driven laboratory operations

Next-Generation Platform Extends LIMS with Agentic AI and Cloud-Native Automation to Improve Efficiency, Reduce Errors and Gain Deeper Insight from Data. Learn More from LabVantage Leadership at Pittcon 2026
Manufacturing

Schütz to build automated IBC production facility at BASF's Ludwigshafen headquarters

Packaging specialist Schütz has signed an agreement with BASF to construct a highly automated intermediate bulk container manufacturing and storage facility directly adjacent to the chemical giant's main plant in Ludwigshafen, enabling round-the-clock just-in-time delivery
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

LGM Pharma announces $9 million investment into Colorado and Texas manufacturing facilities

The investment marks the second phase of the the company's expansion, funding facility upgrades to increase capacity for suppository, semi-solid and oral solid dose and differentiating LGM in the US CDMO market, says CEO Prasad Raje, speaking exclusively to Manufacturing Chemist
Subscribe now